Warby Parker (WRBY) Total Non-Current Liabilities (2020 - 2026)
Warby Parker's (WRBY) quarterly Total Non-Current Liabilities came in at $359.0 million in Q1 2026, up 9.67% YoY from $327.4 million in Q1 2025, and up 2.03% on a QoQ basis from $351.9 million in Q4 2025.
Warby Parker (WRBY) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Warby Parker (WRBY) has 7 years of Total Non-Current Liabilities data on file, last reported at $359.0 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 9.67% year-over-year to $359.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $359.0 million (up 9.67% YoY) and the FY2025 annual result came in at $351.9 million, up 4.89% from the prior year.
- Total Non-Current Liabilities rose to $359.0 million in Q1 2026, from $351.9 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $359.0 million in Q1 2026 to a low of $258.2 million in Q2 2023.
- A 5-year average of $296.6 million and a median of $280.4 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 81.31% — and 2023, when it slipped 1.12%.
- Tracing WRBY's Total Non-Current Liabilities over 5 years: stood at $280.4 million in 2022, then decreased by 1.12% to $277.3 million in 2023, then rose by 21.0% to $335.5 million in 2024, then rose by 4.89% to $351.9 million in 2025, then advanced by 2.03% to $359.0 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $359.0 million (Q1 2026), $351.9 million (Q4 2025), and $336.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 1.92 Bn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 48.34 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | 6.34 Bn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 985.45 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 17.56 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 996.30 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 8.96 Bn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 3.98 Bn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 12.41 Bn |
| 10 | Warby Parker | 3.41 Bn | 3.12 Bn | 136.46 Mn | 378.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 378.92 Mn |
| Mar 31, 2026 | 359.03 Mn |
| Dec 31, 2025 | 351.88 Mn |
| Sep 30, 2025 | 335.95 Mn |
| Jun 30, 2025 | 339.28 Mn |
| Mar 31, 2025 | 327.39 Mn |
| Dec 31, 2024 | 335.47 Mn |
| Sep 30, 2024 | 300.22 Mn |
| Jun 30, 2024 | 287.72 Mn |
| Mar 31, 2024 | 275.53 Mn |
| Dec 31, 2023 | 277.26 Mn |
| Sep 30, 2023 | 268.91 Mn |
| Jun 30, 2023 | 258.18 Mn |
| Mar 31, 2023 | 259.96 Mn |
| Dec 31, 2022 | 280.39 Mn |
| Sep 30, 2022 | 264.37 Mn |
| Jun 30, 2022 | 259.60 Mn |
| Mar 31, 2022 | 261.57 Mn |
| Dec 31, 2021 | 154.65 Mn |
| Sep 30, 2021 | 165.33 Mn |